Advertisement
Canada markets closed

  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CAD/USD

    0.7323
    -0.0001 (-0.01%)
     

  • CRUDE OIL

    83.83
    +0.26 (+0.31%)
     

  • Bitcoin CAD

    87,976.61
    +346.24 (+0.40%)
     

  • CMC Crypto 200

    1,392.87
    +10.30 (+0.74%)
     

  • GOLD FUTURES

    2,346.10
    +3.60 (+0.15%)
     

  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ futures

    17,771.75
    +204.25 (+1.16%)
     

  • VOLATILITY

    15.37
    -0.60 (-3.76%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • NIKKEI 225

    37,813.17
    +184.69 (+0.49%)
     

  • CAD/EUR

    0.6825
    +0.0004 (+0.06%)
     

NASDAQ: ODT Investor Notice: Update in Lawsuit against Odonate Therapeutics, Inc. announced by Shareholders Foundation

Shareholders Foundation, Inc.
·2 min read

SAN DIEGO, Aug. 10, 2021 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces an update in the lawsuit that is pending for certain investors in Odonate Therapeutics, Inc. (NASDAQ: ODT) shares.

Investors, who purchased shares of Odonate Therapeutics, Inc. (NASDAQ: ODT) prior to December 2017 and continue to hold any of their NASDAQ: ODT shares, have also certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1 (858) 779-1554.

On September 16, 2020, a lawsuit was filed against Odonate Therapeutics, Inc. (NASDAQ: ODT) over alleged Securities Laws Violations. The plaintiff alleged that the defendants made false and/or misleading statements and/or failed to disclose that tesetaxel was not as safe or well-tolerated as the Company had led investors to believe, that consequently, tesetaxel's commercial viability as a cancer treatment was overstated, and that as a result, the Company's public statements were materially false and misleading at all relevant times.

On February 16, 2021, an amended complaint was filed and on April 13, a second amended complaint was filed. On May 13, 2021, the defendants filed a motion to dismiss the second amended complaint.

On August 4, the Court denied the defendants' motion to dismiss.

Those who purchased Odonate Therapeutics, Inc. (NASDAQ: ODT) shares should contact the Shareholders Foundation, Inc.

CONTACT:
Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
mail@shareholdersfoundation.com
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108

The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.